
Compounded GLP-1 RA drugs: GLP-1 RA drugs are no longer in shortage, but compounding customized versions of them may continue, part 1
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
The U.S. Food and Drug Administration has ruled GLP-1 RA drugs are no longer in shortage. That ruling affects how
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.















